John Kerr posted in bioethics • clinical trials • ethics • LCT • Living Cell Technologies • Parkinson's disease • xenotransplatation on February 20th, 2014.
An Auckland biotech company is putting its trial of an experimental Parkinson’s disease treatment on hold following the withdrawal of previous animal research. Living Cell Technologies (LCT) has suspended patient recruitment for a clinical trial testing the xenotransplantation of specially encapsulated pig-derived cells (NTCELL) as a treatment for Parkinson’s disease. Earlier research from the company had […]
Continue reading “NZ Parkinson’s trial on hold – experts respond”